首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Targeting tropomyosin receptor kinase for cancer therapy
【24h】

Targeting tropomyosin receptor kinase for cancer therapy

机译:针对癌症治疗的刺激素受体激酶

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

NTRKs and their expression product tropomyosin receptor kinases (Trks) are widely distributed in mammals. While neural growth factor (NGF)-induced normal Trk activation plays a key role in nerve growth, NTRK alternations occurring in tumor cells were highly correlated to tumor progression and invasion. Recent clinical data from several pan-Trk inhibitors have demonstrated potential and broad applications in various cancers. This intrigues us to summarize the development of inhibitors targeting Trks with different mechanisms of action and their applications in cancer therapy. We believe that this perspective would be of great help in investigating novel anticancer drugs with better therapeutic index. (C) 2019 Published by Elsevier Masson SAS.
机译:NTRKS及其表达产品对哺乳动物的广泛分布在哺乳动物中。 虽然神经生长因子(NGF)诱导的正常TRK活化在神经生长中起关键作用,但在肿瘤细胞中发生的NTRK交替与肿瘤进展和侵袭高度相关。 来自几种PAN-TRK抑制剂的最近临床数据在各种癌症中表现出潜在和广泛的应用。 这对我们来说综述靶向Trks的抑制剂的发展,其具有不同的作用机制及其在癌症治疗中的应用。 我们认为,这种观点在于调查具有更好治疗指数的新型抗癌药物。 (c)2019年由Elsevier Masson SA发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号